Search clinical trials for: Placebo+%2B+ADT

Total 58119 results

AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Sleep Disorder

United States
Abbott

Terminated

An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Schizophrenia

United States, Argentina, Mexico
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Hepatitis C

Japan
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Hepatitis C

United States
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

Lupus Erythematosus, Systemic

United States, Taiwan, Korea, Republic of, Brazil, France, Poland, Greece, Philippines, Romania, Colombia, Mexico, Bulgaria, Argentina
AbbVie

Recruiting

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

United States, Australia, Canada, Germany, Greece, Japan, Spain, Puerto Rico
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Healthy Volunteers

Canada
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

Japan
Merck Sharp & Dohme LLC

Completed

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
ALK-Abelló A/S
Ergomed; ACM Pivotal Global Central Laboratory

Completed

House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma (MITRA)

Asthma

Germany
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Healthy

Portugal
AbbVie

Completed

A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis

Knee Osteoarthritis | Medial Compartment Knee Osteoarthritis
AbbVie

Completed

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
Abbott

Completed

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine

United States
Synvista Therapeutics, Inc

Terminated

Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure (BENEFICIAL)

Chronic Heart Failure

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
Beijing 302 Hospital

Recruiting

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Chronic Hepatitis B

China
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Suspended

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Novartis Pharmaceuticals
Alliance Foundation Trials, LLC.; RTOG Foundation, Inc.

Active, not recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)

Prostatic Neoplasms

United States, China, Canada, Spain, United Kingdom, Belgium, Japan, Taiwan, Germany, Singapore, Austria, Netherlands, Korea, Republic of, France, Switzerland, Denmark, Sweden, Poland, Czechia
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)

Hepatitis C

United States, France, Poland, Belgium, Germany, Spain, Portugal, Bulgaria, Turkey, Argentina, Brazil, Austria, Netherlands, Slovakia, Puerto Rico
Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

Lupus Erythematosus, Systemic

Spain, United States, Georgia, Serbia, Germany, Portugal, Poland, South Africa, Philippines, Czechia, Puerto Rico, Chile, Japan, Peru
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain (REACT)

Aneurysmal Subarachnoid Hemorrhage

United States, Spain, Israel, Finland, Poland, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Sweden
AbbVie

Active, not recruiting

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Acute Ischemic Stroke

United States, Australia, Canada, Japan, Korea, Republic of, Spain
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Obstructive Sleep Apnea of Adult

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Healthy Subjects

Switzerland
Synvista Therapeutics, Inc

Completed

The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure (BENEFICIAL)

Heart Failure

Netherlands
Synvista Therapeutics, Inc

Terminated

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) (BREAK-DHF-I)

Diastolic Heart Failure

United States
Asahi Kasei Pharma Corporation

Completed

Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer

Postoperative Stage II/III Colon Cancer

Japan
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Endometriosis | Moderate to Severe Endometriosis-associated Pain

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Chronic Hepatitis B

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
European Organisation for Research and Treatment...
NCIC Clinical Trials Group

Unknown

Adjuvant PEG Intron in Ulcerated Melanoma

Ulcerated Melanomas

France, Denmark, Italy, Belgium, Spain, United Kingdom, Netherlands, Austria, Germany, Poland, Switzerland, Portugal
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
FGK Clinical Research GmbH
University Hospital, Saarland

Completed

Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

Hepatitis C, Chronic

Germany
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic

3

Subscribe